NASDAQ:QURE uniQure Q3 2026 Earnings Date & Estimates $25.30 +0.33 (+1.32%) Closing price 10/29/2026 04:00 PM EasternExtended Trading$25.32 +0.02 (+0.10%) As of 04:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. uniQure is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from uniQure in Q3 2026uniQure is expected to post earnings of -$0.9152 per share on revenue of $6.18 million. In the same quarter a year earlier uniQure reported -$1.38 per share on revenue of $3.70 million. uniQure last reported on July 29, 2026, posting -$1.22 per share and missing the -$0.8223 consensus estimate. uniQure has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.9152Expected Revenue$6.18 millionPrior-Year EPS-$1.38Prior-Year Revenue$3.70 millionExpected Revenue Growth+66.8%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.22 (Missed by -$0.3977)Last Quarter Revenue$5.84 millionEPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report uniQure Q3 2026 Earnings FAQ When does uniQure report Q3 2026 earnings? uniQure (NASDAQ:QURE) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is uniQure's Q3 2026 earnings call? uniQure's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for uniQure? Analysts expect uniQure to post earnings of -$0.9152 per share for Q3 2026. How much revenue is uniQure expected to report? The consensus revenue estimate for uniQure is $6.18 million for Q3 2026. uniQure Earnings HeadlinesuniQure (QURE) Expected to Announce Earnings on Wednesday2 hours ago | americanbankingnews.comuniQure (QURE) Stock Could Be Overvalued Despite A Securities InvestigationOctober 29 at 8:03 AM | finance.yahoo.comElon Musk's Intel Deal Already Jumped 177 Percent This YearElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the analyst who flagged Nvidia in 2016 before its 37,800% run, says Musk may announce a new AI partnership by October 30. | Brownstone Research (Ad)uniQure to Report Third Quarter 2026 Financial Results on November 4, 2026October 28 at 7:31 AM | quiverquant.comQuniQure to Announce Third Quarter 2026 Financial ResultsOctober 28 at 7:05 AM | globenewswire.comAnalyzing CollPlant Biotechnologies (NASDAQ:CLGN) and uniQure (NASDAQ:QURE)October 27 at 7:27 AM | americanbankingnews.comSee More uniQure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like uniQure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on uniQure and other key companies, straight to your email. Email Address About uniQureuniQure (NASDAQ:QURE) is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease. uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement. The company also has a clinical-stage pipeline that has included AMT-130, an investigational gene therapy for Huntington’s disease, as well as other programs targeting neurological and neuromuscular disorders. The company was founded in the Netherlands in 1998 as Amsterdam Molecular Therapeutics and adopted the uniQure name in 2012. It maintains operations in the United States and Europe, with research, development and manufacturing capabilities serving its global programs. uniQure is headquartered in Lexington, Massachusetts, and its ordinary shares trade on the Nasdaq Global Select Market under the symbol QURE.View uniQure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Where's the Beef? Trian-Led Buyout Proposal Values Wendy's at $1.4B, But Is It Enough?Alphabet’s Cloud Is Paying Off—But the Bill for Building It Keeps GrowingPlugging In: Vertiv Cashes In On AI DemandGE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.Phillips 66 Posts Strong Earnings But the Stock Doesn't CareConstellation Energy's Nuclear Expansion Gets a $5 Billion Opening, Not a GuaranteeVisa's Toll Booth Keeps Collecting, But the Price Is Rising Upcoming Earnings Marriott International (11/2/2026)Diamondback Energy (11/2/2026)Williams Companies (11/2/2026)Vertex Pharmaceuticals (11/2/2026)Realty Income (11/2/2026)Apple (11/2/2026)Palantir Technologies (11/2/2026)Entergy (11/2/2026)Booking (11/3/2026)Ferrari (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
